RJA
ALNY icon

Raymond James & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Raymond James & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.01M Sell
10,942
-5,315
-33% -$1.38M ﹤0.01% 1972
2024
Q2 		$3.95M Buy
16,257
+1,089
+7% +$172K ﹤0.01% 1756
2024
Q1 		$2.27M Buy
15,168
+882
+6% +$147K ﹤0.01% 2085
2023
Q4 		$2.73M Buy
14,286
+1,875
+15% +$319K ﹤0.01% 1905
2023
Q3 		$2.2M Buy
12,411
+598
+5% +$114K ﹤0.01% 1966
2023
Q2 		$2.24M Buy
11,813
+1,230
+12% +$244K ﹤0.01% 1984
2023
Q1 		$2.12M Sell
10,583
-534
-5% -$112K ﹤0.01% 1999
2022
Q4 		$2.64M Buy
11,117
+500
+5% +$107K ﹤0.01% 1819
2022
Q3 		$2.13M Sell
10,617
-5,524
-34% -$1.05M ﹤0.01% 1924
2022
Q2 		$2.35M Sell
16,141
-16,919
-51% -$2.4M ﹤0.01% 1891
2022
Q1 		$5.4M Sell
33,060
-10,443
-24% -$1.59M ﹤0.01% 1459
2021
Q4 		$7.38M Buy
43,503
+3,802
+10% +$707K 0.01% 1286
2021
Q3 		$7.5M Sell
39,701
-87
-0.2% -$16.3K 0.01% 1234
2021
Q2 		$6.75M Buy
39,788
+3,157
+9% +$462K 0.01% 1301
2021
Q1 		$5.17M Buy
36,631
+2,727
+8% +$410K 0.01% 1410
2020
Q4 		$4.41M Buy
33,904
+2,261
+7% +$302K ﹤0.01% 1410
2020
Q3 		$4.61M Buy
31,643
+1,018
+3% +$145K 0.01% 1273
2020
Q2 		$4.54M Buy
30,625
+4,121
+16% +$556K 0.01% 1246
2020
Q1 		$2.88M Buy
26,504
+24,540
+1,249% +$2.83M ﹤0.01% 1360
2019
Q4 		$226K Buy
+1,964
New +$196K ﹤0.01% 3269
2016
Q3 		– Sell
-4,008
Closed -$222K – 3218
2016
Q2 		$222K Buy
+4,008
New +$253K ﹤0.01% 2589

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's ALNY Position: Q3 2024 in Review

Raymond James & Associates reduced its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q3 2024, selling an estimated $1.38M and leaving 10,942 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Raymond James & Associates first reported a position in ALNY in Q2 2016 and has held it in 21 quarters since. The position peaked at $7.5M in Q3 2021. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Raymond James & Associates held 10,942 shares of Alnylam Pharmaceuticals worth $3.01M as of Q3 2024.
  • Raymond James & Associates sold 5,315 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $1.38M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1972 holding.
  • Raymond James & Associates first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 21 quarters since.
  • Raymond James & Associates's Alnylam Pharmaceuticals position peaked at $7.5M in Q3 2021.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.